The Latest Breaking News from EMA

Watchdog that quit London after Brexit highlights fears over drug-dealing, drunkenness and rowdy behaviour

EMA says relocation of sex workers to area near its HQ could bring problems associated with red light district

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

The early-year market rally witnessed a reversal, with inpouring macro data, the Fed’s hawkish comments, and recessionary fears. However, on the flip side, a bull market can still materialize with economic growth remaining strong. Therefore, we think quality stocks UnitedHealth Group (UNH), Johnson & Johnson (JNJ), and Salesforce (CRM) might…

Project Servator has been designed to disrupt criminality

The biotech industry is well-positioned to witness significant growth on the backs of soaring demands and government spending. Moreover, given the sector’s defensive nature, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and United Therapeutics Corp. (UTHR) might be solid buys in 2023 that could help you set for life.…

The SunEnergy1 Racing Mercedes defended its Bathurst 12 Hour crown despite Jules Gounon being spun by fellow Mercedes driver Maro Engel inside the last hour.

The European Union's drug regulator needs to do more to tackle shortages of some widely-used antibiotics in the region, according to a letter from a group of European patient and consumer organisations reviewed by Reuters on Tuesday.

A variety of different roles are being advertised

The facility is expected to open in just over a year

The European Medicines Agencies (EMA) recommended European countries include new warnings on labels and in package inserts of analgesics, or pain killers, that combine codeine and ibuprofen. This recommendation was agreed at the last meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), held at the end of September 2022.